Search

Your search keyword '"Xu, Fengrui"' showing total 36 results
Start Over Author "Xu, Fengrui"
36 results on '"Xu, Fengrui"'

3. Design and Implementation of UAV Semi-physical Simulation System Based on VxWorks

Author

Hu, Wenxiao, Cong, Wenyuan, Chen, Xinmin, Chen, Mengqiao, Lin, Yue, Xu, Fengrui, Angrisani, Leopoldo, Series Editor, Arteaga, Marco, Series Editor, Chakraborty, Samarjit, Series Editor, Chen, Jiming, Series Editor, Chen, Shanben, Series Editor, Chen, Tan Kay, Series Editor, Dillmann, Rüdiger, Series Editor, Duan, Haibin, Series Editor, Ferrari, Gianluigi, Series Editor, Ferre, Manuel, Series Editor, Jabbari, Faryar, Series Editor, Jia, Limin, Series Editor, Kacprzyk, Janusz, Series Editor, Khamis, Alaa, Series Editor, Kroeger, Torsten, Series Editor, Li, Yong, Series Editor, Liang, Qilian, Series Editor, Martín, Ferran, Series Editor, Ming, Tan Cher, Series Editor, Minker, Wolfgang, Series Editor, Misra, Pradeep, Series Editor, Mukhopadhyay, Subhas, Series Editor, Ning, Cun-Zheng, Series Editor, Nishida, Toyoaki, Series Editor, Oneto, Luca, Series Editor, Panigrahi, Bijaya Ketan, Series Editor, Pascucci, Federica, Series Editor, Qin, Yong, Series Editor, Seng, Gan Woon, Series Editor, Speidel, Joachim, Series Editor, Veiga, Germano, Series Editor, Wu, Haitao, Series Editor, Zamboni, Walter, Series Editor, Zhang, Junjie James, Series Editor, Tan, Kay Chen, Series Editor, Jia, Yingmin, editor, Zhang, Weicun, editor, Fu, Yongling, editor, and Wang, Jiqiang, editor

Published
2023
Full Text
View/download PDF

14. Effect of an Artificial Intelligence Clinical Decision Support System on Treatment Decisions for Complex Breast Cancer

Author

Xu, Fengrui, primary, Sepúlveda, Martín-J., additional, Jiang, Zefei, additional, Wang, Haibo, additional, Li, Jianbin, additional, Liu, Zhenzhen, additional, Yin, Yongmei, additional, Roebuck, M. Christopher, additional, Shortliffe, Edward H., additional, Yan, Min, additional, Song, Yuhua, additional, Geng, Cuizhi, additional, Tang, Jinhai, additional, Purcell Jackson, Gretchen, additional, Preininger, Anita M., additional, and Rhee, Kyu, additional

Published
2020
Full Text
View/download PDF

15. Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

Author

Jiang, Zefei, primary, Song, Erwei, additional, Wang, Xiaojia, additional, Wang, Haibo, additional, Wang, Xiang, additional, Wu, Jiong, additional, Yin, Yongmei, additional, Zhang, Qingyuan, additional, Chen, Jiayi, additional, Che, Wenyan, additional, Chen, Xiaoyuan, additional, Chen, Zhanhong, additional, Fu, Peifen, additional, Geng, Cuizhi, additional, Guo, Baoliang, additional, Hao, Chunfang, additional, He, Yingjian, additional, Jin, Feng, additional, Liao, Ning, additional, Li, Nanlin, additional, Liu, Jian, additional, Liu, Qiang, additional, Liu, Yunjiang, additional, Liu, Yueping, additional, Ma, Jie, additional, Nie, Jianyun, additional, Pan, Yueyin, additional, Song, Chuangui, additional, Sun, Tao, additional, Wang, Kun, additional, Wang, Shu, additional, Wang, Tao, additional, Wang, Xin, additional, Wang, Biyun, additional, Wang, Shusen, additional, Wang, Yongsheng, additional, Xu, Ling, additional, Yan, Min, additional, Yan, Ying, additional, Yuan, Peng, additional, Yang, Junlan, additional, Zhang, Fan, additional, Zhang, Jun, additional, Zhang, Shaohua, additional, Zeng, Xuan, additional, Li, Jianbin, additional, and Xu, Fengrui, additional

Published
2020
Full Text
View/download PDF

19. Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

Author

Xu, Fengrui, primary, Zhang, Yang, additional, Miao, Zhanhui, additional, Zeng, Xiaohua, additional, Wu, Biao, additional, Cai, Li, additional, Liu, Jinping, additional, Wang, Shusen, additional, Hu, Xichun, additional, Zheng, Wenbo, additional, Chen, Zhiyue, additional, Yang, Qing, additional, and Jiang, Zefei, additional

Published
2020
Full Text
View/download PDF

25. Artificial Intelligence Treatment Decision Support For Complex Breast Cancer Among Oncologists With Varying Expertise

Author

Xu, Fengrui, primary, Sepúlveda, Martín-José, additional, Jiang, Zefei, additional, Wang, Haibo, additional, Li, Jianbin, additional, Yin, Yongmei, additional, Liu, Zhenzhen, additional, Roebuck, M. Christopher, additional, Shortliffe, Edward H., additional, Yan, Min, additional, Song, Yuhua, additional, Geng, Cuizhi, additional, Tang, Jinhai, additional, and Rhee, Kyu, additional

Published
2019
Full Text
View/download PDF

29. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

Author

Xu, Fengrui, primary, Zhang, Yang, additional, Miao, Zhanhui, additional, Zeng, Xiaohua, additional, Wu, Biao, additional, Cai, Li, additional, Liu, Jinping, additional, Wang, Shusen, additional, Hu, Xichun, additional, Zheng, Wenbo, additional, Chen, Zhiyue, additional, Yang, Qing, additional, and Jiang, Zefei, additional

Published
2019
Full Text
View/download PDF

32. Supramolecular Assembly Based on Calix(4)arene and Aggregation‐Induced Emission Photosensitizer for Phototherapy of Drug‐Resistant Bacteria and Skin Flap Transplantation

Author

Wang, Rui‐Peng, Liu, Wenbin, Wang, Xiaoxuan, Shan, Guogang, Liu, Tuozhou, Xu, Fengrui, Dai, Honglian, Qi, Chunxuan, Feng, Hai‐Tao, and Tang, Ben Zhong

Abstract

Photodynamic therapy as a burgeoning and non‐invasive theranostic technique has drawn great attention in the field of antibacterial treatment but often encounters undesired phototoxicity of photosensitizers during systemic circulation. Herein, a supramolecular substitution strategy is proposed for phototherapy of drug‐resistant bacteria and skin flap repair by using macrocyclic p‐sulfonatocalix(4)arene (SC4A) as a host, and two cationic aggregation‐induced emission luminogens (AIEgens), namely TPE‐QAS and TPE‐2QAS, bearing quaternary ammonium group(s) as guests. Through host–guest assembly, the obtained complex exhibits obvious blue fluorescence in the solution due to the restriction of free motion of AIEgens and drastically inhibits efficient type I ROS generation. Then, upon the addition of another guest 4,4′‐benzidine dihydrochloride, TPE‐QAS can be competitively replaced from the cavity of SC4A to restore its pristine ROS efficiency and photoactivity in aqueous solution. The dissociative TPE‐QAS shows a high bacterial binding ability with an efficient treatment for methicillin‐resistant Staphylococcus aureus(MRSA) in dark and light irradiation. Meanwhile, it also exhibits an improved survival rate for MRSA‐infected skin flap transplantation and largely accelerates the healing process. Thus, such cascaded host–guest assembly is an ideal platform for phototheranostics research. Herein, a supramolecular assembly strategy is proposed for phototherapy of drug‐resistant bacteria and skin flap repair by using macrocyclic p‐sulfonatocalix(4)arene as host and two cationic aggregation‐induced emission luminogens bearing quaternary ammonium groups for guests. Such cascaded host–guest assembly is an ideal platform for phototheranostics research.

Published
2024
Full Text
View/download PDF

33. Concordance, decision impact and guidelines adherence using artificial intelligence in high-risk breast cancer.

Author

Jiang, Zefei, primary, Xu, Fengrui, additional, Sepúlveda, Martín-J., additional, Li, Jianbin, additional, Wang, Haibo, additional, Liu, Zhenzhen, additional, Yin, Yongmei, additional, Yan, Min, additional, Song, Yuhua, additional, Guo, Jiakai, additional, Roebuck, M Christopher, additional, Geng, Cuizhi, additional, and Tang, Jinhai, additional

Published
2018
Full Text
View/download PDF

36. Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study.

Author

Zhao W, Bian L, Wang T, Zhang S, Li J, Xu F, and Jiang Z

Abstract

Objective: Several studies have demonstrated different benefits for patients whose disease progressed despite previous trastuzumab treatment. Due to limited real-world data, we evaluate the effectiveness of anti-human epidermal growth factor receptor 2 (HER2) therapy (lapatinib or trastuzumab) plus chemotherapy or chemotherapy alone in patients who were previously treated with trastuzumab-containing regimens and investigate factors associated with effectiveness. And we further show the effectiveness of the two anti-HER2 therapy groups., Methods: A total of 342 HER2-positive metastatic breast cancer (MBC) patients whose disease progressed during prior anti-HER2 (trastuzumab) and standard chemotherapy therapy from Department of Breast Oncology, the Fifth Medical Center of Chinese PLA General Hospital, from August 2010 to December 2016 were included. Seventy-eight patients received standard chemotherapy only, 148 patients continued to receive trastuzumab and switched to other chemotherapy drugs, and 116 patients received tyrosine-kinase inhibitors (TKIs; lapatinib) and chemotherapy. The main outcome measures were progression-free survival (PFS), overall response rate (ORR), and clinical benefit rate (CBR). Subgroup analyses were conducted to identify patient characteristics associated with the greatest clinical benefit., Results: After a median follow-up of 26.2 (range, 2.0-56.0) months, PFS significantly improved with anti-HER2 therapy compared with chemotherapy alone: median 6.0 months with lapatinib [95% confidence interval (95% CI), 4.53-7.47], 4.5 months with trastuzumab (95% CI, 3.99-5.01) vs . 3.0 months with chemotherapy alone (95% CI, 2.42-3.58); stratified hazard ratio (HR)=0.70, 95% CI, 0.60-0.81; P<0.0001. The ORR values were 33.6%, 25.0% and 12.8 %, respectively, the CBR values were 60.3%, 48.6% and 26.9%, respectively. The effectiveness of lapatinib group and trastuzumab group were further analyzed. In multivariate analysis, lapatinib group was associated with a longer PFS, after controlling other potential confounders (HR=0.68, 95% CI, 0.52-0.90; P=0.006)., Conclusions: The combination of TKIs and chemotherapy was effective in this cohort previously treated with trastuzumab treatment. Therefore, TKIs combined with chemotherapy is an option for Chinese HER2-positive MBC patients previously treated with trastuzumab treatment., (Copyright © 2020 Chinese Journal of Cancer Research. All rights reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results